An extention study of JR-401 in patients with SHOX dificiency

An extention study of JR-401 in short stature patients with SHOX deficiency

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031200425

Enrollment

Registered

2021-03-17

Start date

2020-09-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SHOX deficiency

Interventions

Administer somatropin (recombinant) subcutaneously at 0.35 mg/kg/week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A pediatric Patient who participated in the previous study and completed the visit after 24 months, and who were judged by the principal-investigator or sub-investigator to be safe for transfer to this study from the viewpoint of safety

Exclusion criteria

Exclusion criteria: A pediatric patient with a diagnosis of diabetes (following the Diagnostic Procedure for Diabetes)

Design outcomes

Primary

Measure	Time frame
Safety and efficacy during long-term administration	—

Contacts

Public ContactRyo Ibaraki

JCR Pharmaceuticals Co., Ltd.

clinical_development@jp.jcrpharm.com+81-797-32-8582

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026